Read More

BioCardia Says Based On Interim Results In Autologous CardiAMP Cell Therapy For Treatment Of Heart Failure, Co. Is Exploring Development Of a New Phase 3 Clinical Trial Protocol; CardiAMP HF Trial Showed

BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced a clarification and next steps on its autologous